series-b
Stage
2018
Founded
2
Investors
About
Resistell is developing a phenotypic nanomotion-based diagnostic technology for rapid antibiotic susceptibility testing by measuring changes in bacterial cell movement after antibiotic exposure, providing results within a few hours versus culture-based antibiograms.
Explore Resistell's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.